Mycophenolate Mofetil 500mg ( DrugBank: Mycophenolate mofetil, Mycophenolate )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	2
51	全身性強皮症	1
61	自己免疫性溶血性貧血	1

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05057481 (ClinicalTrials.gov)	September 15, 2021	16/9/2021	Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Autoimmune Hemolytic Anemia;Systemic Lupus Erythematosus	Drug: Mycophenolate Mofetil 500mg;Drug: Rituximab	Assiut University	NULL	Active, not recruiting	18 Years	N/A	All	30	Phase 3	Egypt
2	ChiCTR1800017540	2018-09-01	2018-08-03	A randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvement	A randomized controlled trial for the long-term outcomes of MMF on new onset SLE patients with high titers of anti-dsDNA antibody for reducing main organ involvement	systemic lupus erythematosus	1:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day);2:Hydroxychloroquine (5mg/kg/day) plus prednisone (0.5mg/kg/day) plus Mycophenolate Mofetil 500mg bid;	Ruijin Hospital	NULL	Completed	18	65	Both	1:65;2:65;	Phase 4	China

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04927390 (ClinicalTrials.gov)	December 8, 2021	19/5/2021	Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)	A Randomised Prospective Open Label Pilot Trial Comparing Mycophenolate Mofetil (MMF) With no Immunosuppression in Adults With Limited Cutaneous Systemic Sclerosis	Systemic Sclerosis;Limited Cutaneous Systemic Sclerosis	Drug: Mycophenolate Mofetil 500mg	University College, London	Versus Arthritis	Recruiting	18 Years	N/A	All	120	Phase 2	United Kingdom

61. 自己免疫性溶血性貧血

---

臨床試験数 : 146 /  薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05057481 (ClinicalTrials.gov)	September 15, 2021	16/9/2021	Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Reappraisal of Second-line Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus	Autoimmune Hemolytic Anemia;Systemic Lupus Erythematosus	Drug: Mycophenolate Mofetil 500mg;Drug: Rituximab	Assiut University	NULL	Active, not recruiting	18 Years	N/A	All	30	Phase 3	Egypt